Keywords: Roche, OSI, Tarceva, Taspoglutide, Osiris, Prochymal, JCR

Roche’s Tarceva cleared for NSCLS maintenance in EU; taspoglutide positive in Ph III diabetes trial; milestone for Osiris from JCR

Article | 30 April 2010

Print This

Swiss drug major Roche says that the European Commission has approved its cancer drug Tarceva (erlotinib), marketed under license from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in